---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-022134"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:29:33.129405+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma Q3 net loss $4.2M; LP-184 Phase 1a achieves 48% clinical benefit rate

## Summary
- Net loss $4.2M ($0.39/shr) vs $4.5M loss in Q3 2024; cash $12.4M, runway into Q3 2026.
- LP-184 Phase 1a met all endpoints; 48% clinical benefit rate at therapeutic dose; RP2D set at 0.39 mg/kg.
- FDA Type C meeting provides regulatory path for pediatric CNS trial in ATRT; spironolactone combo strategy confirmed.
- LP-300 HARMONIC trial data presented at Japan Lung Cancer Society; Japan enrollment completed.
- RADR AI platform modules commercial-ready; predictBBB 94.1% accuracy, LBx-AI 86% accuracy for treatment response.

## SEC filing metadata
- accession: 0001493152-25-022134
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000149315225022134/0001493152-25-022134-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000149315225022134/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-022134
- JSON: https://secwatch.observer/filing/0001493152-25-022134.json
- Plain text: https://secwatch.observer/filing/0001493152-25-022134.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.